Diagnostic Immunization With Rabies Vaccine in Patients With PID

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE4

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-04-30

Study Completion Date

2016-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to evaluate diagnostic immunization protocol of rabies vaccine for diagnosis the patients with primary immunodeficiency disorders and study humoral and cellular immune response to rabies vaccine in patients with primary immunodeficiency.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Immune Responses and Immunological Tolerance After Rabies Booster Vaccination in HIV-infected Adults

NCT03228069

Rabies

UNKNOWN NA

Immune Response After Booster Vaccination in HIV - Infected Patients Who Received Rabies Primary Vaccination

NCT01286493

HIV Rabies

COMPLETED NA

Immune Responses After a Four-site Intradermal Rabies Booster Vaccination in HIV-infected Adults

NCT02547727

Rabies

UNKNOWN NA

Safety and Efficacy of Neutralizing Antibodies and Vaccination for Induction of HIV Remission

NCT05769569

HIV-1-infection

WITHDRAWN PHASE1

Safety and Effects of Using Prime-boost HIVIS DNA and MVA-CMDR Vaccine Regimens With or Without Toll-like Receptor 4 Agonist on HIV Reservoirs in Perinatally HIV Infected Children and Youth

NCT04301154

HIV Infections

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Objective Primary objective

: To study diagnostic immunization protocol of rabies vaccine for diagnosis the patients with primary immunodeficiency disorders. Secondary objective

* To study humoral and cellular immune response to rabies vaccine in patients with primary immunodeficiency.
* To study anti-rabies immunization protocol in patients with primary immunodeficiency disorders.

Population Case group: Twenty primary immunodeficiency disease patients that are diagnosed, treated and followed at Allergy and Immunology unit, Department of Pediatrics, Faculty of Medicine, Chulalongkorn University.

Control group: Twenty healthy subjects who have no underlying disease and age-matched with case patients. Inclusion and exclusion criteria

Vaccine :

* Verorab® (PVRV; Purified Vero Cell Vaccine) 0.5 ml intramuscular
* Standard intramuscular regimen: ESSEN on days 0, 3, 7, 14, 28 and booster at 1 year later on days 360 and 363

Immunological evaluations :

1. Humoral immune response :

on 5 ml blood samples will be collected for antibody determination days 0, 14, 28, 90, 360, 367 and 374. Neutralizing antibodies will be determined blindly using the rapid fluorescent focus inhibition test (RFFIT) at Queen Saovabha Memorial Institute. Rabies neutralizing antibody will be reported in IU/ml The protective antibody level are defined rabies neutralizing antibody ≥ 0.5 IU/ml .
2. Cellular mediated immune response :

On 5 ml blood samples will be collected for antibody determination days 14, 28, 90, 360, 367 and 374. Lymphocyte proliferation response to rabies antigen will be determined by using 3H-thymidine incorporation assay.

The responder criteria are defined as stimulation index (SI index) ≥ 2.0 was considered as evidence of antigen-induced lymphocyte proliferation.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Primary Immunodeficiency

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Rabies vaccination

* Verorab® (PVRV; Purified Vero Cell Vaccine) 0.5 ml intramuscular
* Standard intramuscular regimen: ESSEN on days 0, 3, 7, 14, 28 and booster at 1 year later on days 360 and 363

Group Type EXPERIMENTAL

Verorab® (PVRV; Purified Vero Cell Vaccine)

Intervention Type BIOLOGICAL

* Verorab® (PVRV; Purified Vero Cell Vaccine) 0.5 ml intramuscular
* Standard intramuscular regimen: ESSEN on days 0, 3, 7, 14, 28 and booster at 1 year later on days 360 and 363

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Verorab® (PVRV; Purified Vero Cell Vaccine)

* Verorab® (PVRV; Purified Vero Cell Vaccine) 0.5 ml intramuscular
* Standard intramuscular regimen: ESSEN on days 0, 3, 7, 14, 28 and booster at 1 year later on days 360 and 363

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Case group

1. Patient with primary immunodeficiency diseases who follows up at Division of pediatric allergy and immunology unit, King Chulalongkorn Memorial Hospital
2. Subject or father/mother/legally acceptable representative properly informed about the study and having signed the informed consent form.
3. Subject is able to comply with the follow-up schedule of the protocol
* Control group

1. Subject is healthy (from history and physical examination)
2. Subject do not has underlying diseases.
3. Subject do not has primary and secondary immunodeficiency diseases
4. Subject is not receiving immunosuppressive therapy or cytotoxic drugs
5. Subject or father/mother/legally acceptable representative properly informed about the study and having signed the informed consent form.
6. Subject is able to comply with the follow-up schedule of the protocol
7. Age more than 12 month old to 60 years old

Exclusion Criteria

1. Reported history of previous rabies immunization or Rabies neutralizing antibody (Rabies Nab) \> 0.5 IU/ml
2. Subject is unable to comply with the follow-up schedule of the protocol
3. Pregnancy
4. Body temperature more than 38 degree celcius at screening visit

Minimum Eligible Age

12 Months

Maximum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes